NAUTIKA1 study is a phase II umbrella trial focusing on the neoadjuvant therapy including ALK, ROS1, NTRK, BRAF V600E and PD-L1 positive in stage II-III NSCLC patients. This evidence concerns the gene BRAF and non-small cell lung carcinoma.